ITGRNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Integer Holdings Corp
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 4, 2026
$126.75+0.05 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 34.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
27.0%+0.4 pts over 5 years
Operating margin
11.9%+0.7 pts over 5 years
Net margin
5.5%−1.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.0% | +11.7% | +11.5% | +8.8% | |
| Gross profit | +9.0% | +13.1% | +11.9% | +7.8% | |
| Operating income | +6.3% | +25.2% | +12.9% | +32.6% | |
| Net income | -14.3% | +15.7% | +5.9% | – | |
| EPS, diluted | -14.0% | +13.2% | +4.4% | – | |
| Free cash flow | +5.3% | +36.1% | -4.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 0.8% | 6.4% | 6.1% | |
| Return on assets | 0.2% | 3.3% | 3.2% | |
| Current ratio | 2.79 | 2.64 | 3.32 | |
| Debt to equity | 2.39 | 0.58 | 0.68 | |
| Net debt to EBITDA | 9.15× | 3.41× | 3.32× | |
| Interest coverage | 1.4× | 3.2× | 5.1× | |
| Inventory turnover | 3.1× | 5.0× | 5.4× | |
| Capex to revenue | 5.5% | 4.4% | 4.9% | |
| Diluted shares | 31M | 33M | 36M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Integer generated $854.61M from operations and spent $494.53M on capital expenditure, dividends and share buybacks. 90% of that went back into the business.
Generated
$854.61M
Used
$494.53M
Capital expenditure$444.52M90%Dividends$00%Share buybacks$50.01M10%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin5.5%
×Asset turnover0.57×
×Equity multiplier1.93×
=Return on equity, FY20256.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 5.5% | 0.57× | 1.93× | 6.1% |
| FY2024 | 7.0% | 0.57× | 1.92× | 7.6% |
| FY2023 | 5.8% | 0.54× | 1.95× | 6.2% |
| FY2022 | 5.0% | 0.50× | 1.94× | 4.8% |
| FY2021 | 7.9% | 0.49× | 1.89× | 7.4% |
| FY2020 | 7.2% | 0.45× | 1.95× | 6.4% |
| FY2019 | 7.7% | 0.54× | 2.11× | 8.7% |
| FY2018 | 13.8% | 0.47× | 2.65× | 17.2% |
| FY2017 | 5.9% | 0.40× | 3.51× | 8.2% |
| FY2016 | 0.6% | 0.37× | 3.69× | 0.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$102.81M
- Cash generatingOperating cash flow above zero$196.15M
- Return on assets improvedROA up on the prior year4.1% → 3.3%
- Earnings backed by cashOperating cash flow above net income$196.15M vs $102.81M
- Less leverageLong-term debt to assets fell31.8% → 34.8%
- Better liquidityCurrent ratio rose2.95 → 3.32
- No dilutionShare count did not rise36M → 36M
- Gross margin improvedGross margin up on the prior year26.74% → 26.99%
- More efficientAsset turnover rose0.58 → 0.60